Accurate and early disease detection is key to improving healthcare, but current diagnostic tests often lack precision, leading to delays, false alarms, and higher healthcare costs. Our innovative solution offers the main benefit of substantially improving diagnostic accuracy at the earliest stages, using advanced nanotechnology and CRISPR to develop ultra-sensitive tests that detect trace levels of disease markers. These tests are designed to integrate seamlessly with existing hospital equipment, making them easy to adopt across various applications.
This project will assess the commercial potential of our technology. We’ll analyze the market to find where our diagnostics deliver the most value. We’ll refine the technology with clinical and industry experts and validate it through testing. We’ll also set quality standards, secure patents, and build partnerships to scale manufacturing.
Our technology has the potential to transform healthcare, reduce costs, and improve patient outcomes across diverse medical fields by enabling faster, more reliable disease detection.
